Mutant p53: A therapeutic target for the treatment of triple-negative breast cancer?

被引：0
|
作者：
Synnott, Naoise C.
Pierce, Aisling
Mullooly, Maeve
Caiazza, Francesco
McGowan, Patricia M.
O'Donovan, Norma
Crown, John
Duffy, Michael J.
机构：
[1] Univ Coll Dublin, Educ & Res Ctr, St Vincents Univ Hosp, Dublin 2, Ireland
[2] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland
[3] Dublin City Univ, Natl Inst Cellular Biotechnol, Mol Therapeut Canc Ireland, Dublin 9, Ireland
[4] Irish Clin Oncol Res Grp, Dublin, Ireland
[5] Mol Therapeut Canc Ireland, Dublin, Ireland
[6] Univ Coll Dublin, Clin Res Ctr, St Vincents Univ Hosp, Dublin 2, Ireland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1118
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1118
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Mutant p53 as a Therapeutic Target for the Treatment of Triple-Negative Breast Cancer
    Synnott, N.
    Crown, J.
    Duffy, M. J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E41 - E41
  • [2] Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott, N. C.
    Murray, A.
    McGowan, P. M.
    Kiely, M.
    Kiely, P. A.
    O'Donovan, N.
    O'Connor, D. P.
    Gallagher, W. M.
    Crown, J.
    Duffy, M. J.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (01) : 234 - 246
  • [3] Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Prelinical investigation with the anti-p53 drug, APR-246.
    Synnott, Naoise C.
    Murray, Alyson M.
    O'Donovan, Norma
    Crown, John
    Duffy, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007
    Synnott, Naoise C.
    Bauer, Matthias R.
    Madden, Stephen
    Murray, Alyson
    Klinger, Rut
    O'Donovan, Norma
    O'Connor, Darran
    Gallagher, William M.
    Crown, John
    Fersht, Alan R.
    Duffy, Michael J.
    CANCER LETTERS, 2018, 414 : 99 - 106
  • [5] Generation of a transcriptome of oncogenic mutant p53 in triple-negative breast cancer
    Steele, Rebecca E.
    McDade, Simon S.
    Mullan, Paul B.
    CANCER RESEARCH, 2017, 77
  • [6] Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53
    Scarpetti, Lauren
    Oturkar, Chetan C.
    Juric, Dejan
    Shellock, Maria
    Malvarosa, Giuliana
    Post, Kathryn
    Isakoff, Steven
    Wang, Nancy
    Nahed, Brian
    Oh, Kevin
    Das, Gokul M.
    Bardia, Aditya
    ONCOLOGIST, 2023, : 358 - 363
  • [7] The benefits of Didox in triple negative breast cancer treatment targeting mutant p53
    Sultana, Nahid
    Wilson, Elizabeth A.
    Shah, Khyati N.
    Elford, Howard L.
    Faridi, Jesika S.
    CANCER RESEARCH, 2020, 80 (16)
  • [8] P53 GENE COULD BE A NEW EFFECTIVE THERAPEUTIC TARGET IN TRIPLE-NEGATIVE BREAST CANCER: A META-ANALYSIS
    Guo, F.
    Xie, X.
    Liu, Z.
    Liu, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 55 - 55
  • [9] Targeting mutant p53 with COTI-2: A new approach for the treatment of patients with triple-negative breast cancer?
    Synnott, Naoise C.
    O'Connell, David J.
    Crown, John
    Duffy, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Targeting mutant p53 with PK11007: A new approach for the treatment of patients with triple-negative breast cancer?
    Synnott, Naoise C.
    Bauer, Matthias R.
    Madden, Stephen F.
    Murray, Alyson M.
    Klinger, Rut
    O'Donovan, Norma
    O'Connor, Darran
    Gallagher, William M.
    Crown, John
    Fersht, Alan R.
    Duffy, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345